Bausch Health Companies Inc Quick Ratio (BHC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Bausch Health Companies Inc   (NYSE: BHC)

Bausch Health Companies Inc 's Quick Ratio

BHC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.39 below Bausch Health Companies Inc average.

Within Major Pharmaceutical Preparations industry 400 other companies have achieved higher Quick Ratio than Bausch Health Companies Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2510 to 2855.

Explain Quick Ratio?
How much Cash & cash equivalents BHC´s has?
What are BHC´s Current Liabilities?




BHC Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 136.72 % 46.39 % -83.2 % 7.99 % 35.34 %
Y / Y Cash & cash equivalent Change 5.67 % 14.55 % 10.84 % 81.92 % 190.25 %
Quick Ratio MRQ 0.39 0.67 1.01 0.77 0.87
BHC's Total Ranking # 2855 # 2510 # 1789 # 641 # 491
Seq. Current Liabilities Change 143.48 % 48.42 % -23.84 % -13.99 % 50.57 %
Seq. Cash & cash equivalent Change 40.49 % -0.76 % 0.08 % -24.26 % 52.29 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 401
Healthcare Sector # 762
Overall Market # 2855


Quick Ratio Statistics
High Average Low
3.95 0.58 0.13
(Mar 31 2015)   (Dec 31 2016)




Financial Statements
Bausch Health Companies Inc 's Current Liabilities $ 4,687 Millions Visit BHC's Balance sheet
Bausch Health Companies Inc 's Cash & cash equivalent $ 1,825 Millions Visit BHC's Balance sheet
Source of BHC's Sales Visit BHC's Sales by Geography


Cumulative Bausch Health Companies Inc 's Quick Ratio

BHC's Quick Ratio for the trailling 12 Months

BHC Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -23.67 % -42.82 % -49.02 % 80.07 % 79.5 %
Y / Y Cash & cash equivalent TTM Growth 20.58 % 55.5 % 69.7 % 78.69 % 56.87 %
Quick Ratio TTM 0.6 0.82 0.87 0.42 0.38
Total Ranking TTM # 4074 # 2998 # 2110 # 864 # 726
Seq. Current Liabilities TTM Growth 39.2 % 9.69 % -50.5 % 1 % 4.28 %
Seq. Cash & cash equivalent TTM Growth 1.74 % 3.01 % 2.39 % 12.37 % 31.19 %


On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $4,687.00 millions, cumulative Quick Ratio decreased to 0.6 above the BHC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 441 other companies have achieved higher Quick Ratio than Bausch Health Companies Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2998 to 4074.

Explain Quick Ratio?
How much Cash & cash equivalents BHC´s has?
What are BHC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 442
Healthcare Sector # 907
Within the Market # 4074


trailing twelve months Quick Ratio Statistics
High Average Low
1.21 0.3 0.12
(Mar 31 2015)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions
Inmed Pharmaceuticals Inc  1.00 $ 2.240  Millions$ 2.235  Millions
Nkarta Inc   1.00 $ 24.958  Millions$ 24.924  Millions
Inovio Pharmaceuticals Inc   1.00 $ 36.700  Millions$ 36.678  Millions
Jazz Pharmaceuticals Plc  0.98 $ 2,199.800  Millions$ 2,239.400  Millions
Akebia Therapeutics Inc   0.97 $ 155.548  Millions$ 160.865  Millions
Syndax Pharmaceuticals Inc   0.95 $ 342.883  Millions$ 360.284  Millions
Nurix Therapeutics Inc   0.94 $ 67.840  Millions$ 72.020  Millions
Theriva Biologics inc   0.94 $ 11.337  Millions$ 12.111  Millions
Geron Corporation  0.92 $ 64.781  Millions$ 70.331  Millions
Zomedica Corp   0.84 $ 7.605  Millions$ 9.002  Millions
Cocrystal Pharma Inc   0.83 $ 2.169  Millions$ 2.616  Millions
Harrow Inc   0.82 $ 83.889  Millions$ 102.171  Millions
Cue Biopharma Inc   0.82 $ 17.414  Millions$ 21.218  Millions
Zoetis Inc   0.81 $ 1,676.000  Millions$ 2,061.000  Millions
Organogenesis Holdings Inc   0.81 $ 46.097  Millions$ 56.963  Millions
Bridgebio Pharma Inc   0.81 $ 720.160  Millions$ 890.648  Millions
Nrx Pharmaceuticals Inc   0.79 $ 26.686  Millions$ 33.874  Millions
Oncolytics Biotech Inc   0.79 $ 4.115  Millions$ 5.225  Millions
Moleculin Biotech Inc   0.78 $ 7.262  Millions$ 9.313  Millions
Seres Therapeutics Inc   0.78 $ 15.594  Millions$ 20.031  Millions
Travere Therapeutics Inc   0.77 $ 117.735  Millions$ 152.025  Millions
Arcus Biosciences Inc   0.77 $ 153.000  Millions$ 198.000  Millions
Alkermes Plc   0.77 $ 511.529  Millions$ 662.091  Millions
Integrated Biopharma Inc  0.77 $ 4.471  Millions$ 5.802  Millions
Cyclerion Therapeutics Inc   0.75 $ 1.391  Millions$ 1.843  Millions
Dar Bioscience Inc   0.75 $ 12.618  Millions$ 16.923  Millions
Heron Therapeutics Inc   0.70 $ 64.643  Millions$ 92.145  Millions
Amphastar Pharmaceuticals Inc   0.70 $ 331.903  Millions$ 476.848  Millions
Axsome Therapeutics Inc   0.69 $ 319.850  Millions$ 460.446  Millions

Date modified: 2026-09-15T07:25:10+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.